#USA #New York #Clinical Trials #Soleno Therapeutics #DCCR

Legal Concerns Surrounding Soleno Therapeutics

In the world of pharmaceuticals, regulatory approvals hinge on the robustness of clinical trial data. Soleno Therapeutics, Inc. (NASDAQ: SLNO) now finds itself in hot water as a class action lawsuit unfolds, targeting the very foundation of the approval for its sole product, DCCR (marketed as VYKAT XR). Designed to treat hyperphagia in individuals with Prader-Willi syndrome, DCCR's journey to market is now questioned amid allegations of sham clinical trials, potentially shaking investor confidence and impacting stock values.

The Allegations

Levi & Korsinsky, LLP, the firm representing aggrieved investors, has explicitly stated that the lawsuit seeks to recover damages from those who purchased Soleno's securities between March 26 and November 4, 2025. The core of the complaint focuses on alleged misrepresentations regarding the integrity of clinical trials and drug safety. Investors are urged to evaluate their options to recuperate losses potentially incurred due to these claims.

Trial Integrity at Stake

The approval of DCCR hinges on its Phase 3 clinical trial outcomes, particularly a pivotal randomized withdrawal study. The integrity of this study is essential because it serves as a major component of the FDA’s assessment for drug safety and efficacy. Critics allege that numerous deficiencies in the trial could undermine this essential approval. The pivotal study involved only 77 participants, an unusually low sample size, with critics claiming skewed enrollments from only one clinical site.

Moreover, the initial Phase 3 trial (DESTINY PWS), which included 127 participants, reportedly did not meet its primary endpoints for hyperphagia improvement, raising questions about DCCR’s efficacy. Critics have pointed out potential placebo bias, as unblinding occurred because of side effects like hypertrichosis (excessive hair growth) and noticeable differences between the drug and placebo smells. Many investigators from prominent academic centers have expressed skepticism over prescribing the medication, indicating a broader concern regarding its safety profile.

Safety Concerns and Concealment Allegations

An alarming aspect of the lawsuit involves accusations that Soleno downplayed critical safety issues related to fluid retention — a known effect of diazoxide, DCCR’s active ingredient. The complaint suggests that two patients experienced severe adverse effects such as pulmonary edema, possibly resulting in heart failure during the Phase 3 trial; however, these incidents were allegedly downplayed by Soleno management.

Investors were continually reassured about DCCR's safety, with claims that "no new safety signals" had appeared post-marketing. The lawsuit stresses the importance of revealing any linear increases in diabetes and prediabetes markers observed during treatment, an indication that could pose serious health risks to patients.

Implications for Investors

The securities class action filed against Soleno Therapeutics could have significant ramifications. With a deadline set for investors to seek lead plaintiff status by May 5, 2026, the urgency to assess potential recovery options is evident. As Joseph E. Levi, Esq., points out, questions surrounding the accuracy of information disclosed to investors regarding clinical data integrity are crucial in this matter.

If proven, the allegations could lead to substantial penalties for Soleno and provide a basis for investors to claim compensation for their losses. The unfolding events not only raise concerns about the company but also draw attention to the broader implications for clinical trial transparency in the pharmaceutical industry.

As this situation develops, stakeholders and investors alike will be closely monitoring the outcome of this case, which emphasizes the critical intersection of clinical integrity, regulatory compliance, and market trust in the healthcare sector.